TR201813644T1 - Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. - Google Patents
Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. Download PDFInfo
- Publication number
- TR201813644T1 TR201813644T1 TR2018/13644A TR201813644A TR201813644T1 TR 201813644 T1 TR201813644 T1 TR 201813644T1 TR 2018/13644 A TR2018/13644 A TR 2018/13644A TR 201813644 A TR201813644 A TR 201813644A TR 201813644 T1 TR201813644 T1 TR 201813644T1
- Authority
- TR
- Turkey
- Prior art keywords
- prostate
- endoradiotherapy
- specific membrane
- membrane antigen
- prostate cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar açıklanmaktadır.
Description
Tarifname ile belgeye dahil edilen referanslar arasindaki herhangi bir tutarsizlik halinde, tarifname (dahil edilmis referansa dayali olabilecek ilgili tadiller dahil) geçerli olacaktir. Aksi belirtilmedikçe, terimler burada alanda kabul edilen standart anlamlariyla kullanilmaktadir. Burada çesitli terimler için standart kisaltmalar kullanilmaktadir. M.G., Ray, S., Mease, R.C., Foss, C. Prostat-spesifik membran antijenin (PSMA) etiketlenmis inhibitörleri, biyolojik degerlendirme ve görüntüleme ajanlarinin kullanimi hakkinda, yayin tarihi: 31/; Chandran S.S., Ray S., Denmeade S.R., Pomper M.G., Mease R.C., Prostat kanserinin tedavisi için prostat-spesifik membran antijen hedefli nanopartiküller hakkinda, yayin M.G., Mease R.C.; Ray S., Chen Y. PSMA hedefli bilesikler ve bunlarin kullanimlari hakkinda, yayin tarihi: 23/; Banerjee, S. R., Foss, C. A., Pullambhatla, M., Wang, Y., Srinivasan, S., Hobbs, R. F., Baidoo, K. E., Brechbiel, M. W., Nimmagadda, S., Mease, R. C., Sgouros, G. Ve Pomper, M. G. (2015) Dozametre tahminleri bakimindan prostat- Spesifik membran anti Jenin 86Y -etiketli inhibitörlerinin klinik öncesi degerlendirmesi. Journal of nuclear medicine 56, 628-34; Benesova, M., Schafer, M., Bauder-Wust, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., ve Eder, M. (2015) Prostat Kanserinin Görüntülenmesi ve Endoradyoterapisi için Optimize edilmis Baglayici Parçaya sahip Özel olarak Hazirlanmis DOTA-Konjüge PSMA Inhibitörünün Klinik öncesi Degerlendirmesi. Journal of nuclear medicine 56, 914-20; Tykvart, J., Schimer, J., Jancarik, A., Barinkova, J., Navratil, V., Starkova, J., Sramkova, K., Konvalinka, J., Majer, P., ve Sacha, P. (2015) Glütamat Karboksipeptidaz için Seçilmis Yüksek Etkili Üre Bazli Ekzositoz Baglama Weineisen, M., Simecek, J., Schottelius, M., Schwaiger, M. ve Wester, H.-J. (2014) Prostat kanserinin fonkSIy0nel görüntülenmesi ve endoradyoterapisi için DOTAGA-konjüge PSMA ligantlarinin sentezi ve klinik öncesi degerlendirmesi. EJNMMI Res 4,1-15. Yukaridaki bulusun konusu, daha net anlasilmasi için resimler ve örneklerle ayrintili sekilde açiklanmis olsa da, alanda bilgi sahibi kisiler ekteki istemlerin kapsaminda belirli degisiklikler ve tadiller yapilabilecegini anlayacaktir. TR TR TR TR TR TR TR TR TR TR TR TR
Claims (1)
1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201813644T1 true TR201813644T1 (tr) | 2018-11-21 |
Family
ID=59899817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/13644A TR201813644T1 (tr) | 2016-03-22 | 2017-03-22 | Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (tr) |
| EP (3) | EP4385981A1 (tr) |
| JP (4) | JP7073270B2 (tr) |
| KR (4) | KR20250057132A (tr) |
| CN (3) | CN109311827B (tr) |
| AU (1) | AU2017238181B2 (tr) |
| BR (1) | BR112018069507A2 (tr) |
| CA (1) | CA3018709A1 (tr) |
| CL (1) | CL2018002683A1 (tr) |
| CY (1) | CY1124487T1 (tr) |
| DK (2) | DK3925952T3 (tr) |
| ES (2) | ES2877572T3 (tr) |
| FI (1) | FI3925952T3 (tr) |
| HR (2) | HRP20211386T1 (tr) |
| HU (2) | HUE065327T2 (tr) |
| LT (2) | LT3433238T (tr) |
| MX (1) | MX384823B (tr) |
| PH (1) | PH12018502048A1 (tr) |
| PL (2) | PL3925952T3 (tr) |
| PT (2) | PT3925952T (tr) |
| RS (2) | RS65188B1 (tr) |
| RU (2) | RU2021115958A (tr) |
| SA (1) | SA518400103B1 (tr) |
| SI (2) | SI3925952T1 (tr) |
| TR (1) | TR201813644T1 (tr) |
| WO (1) | WO2017165473A1 (tr) |
| ZA (1) | ZA201806389B (tr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017311510B2 (en) | 2016-08-10 | 2021-11-18 | Cancer Targeted Technology Llc | Chelated PSMA inhibitors |
| MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| BR112020011727A2 (pt) | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| US20200297877A1 (en) * | 2017-12-13 | 2020-09-24 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| EP3749663A1 (en) * | 2018-02-06 | 2020-12-16 | Universität Heidelberg | Fap inhibitor |
| US11813340B2 (en) * | 2018-02-06 | 2023-11-14 | The Johns Hopkins University | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| HRP20230604T1 (hr) | 2018-03-30 | 2023-09-29 | Futurechem Co., Ltd. | Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate |
| WO2019240884A2 (en) | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| EP3856261A1 (en) * | 2018-09-28 | 2021-08-04 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| PH12021553284A1 (en) * | 2019-07-02 | 2022-08-01 | Advanced Accelerator Applications Italy Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| CN114096526A (zh) * | 2019-07-02 | 2022-02-25 | 诺华股份有限公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| JP2023522983A (ja) * | 2020-04-24 | 2023-06-01 | ラジオメディックス インコーポレイテッド | 前立腺がんの診断および処置のための組成物、キットおよび方法 |
| IL297323A (en) | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| WO2022108992A1 (en) * | 2020-11-17 | 2022-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| EP4247798B1 (en) * | 2020-11-19 | 2025-08-27 | Novartis AG | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| US20240299596A1 (en) * | 2021-06-17 | 2024-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| AU2023413150A1 (en) * | 2022-12-21 | 2025-06-26 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700234T3 (es) * | 2007-06-26 | 2019-02-14 | Univ Johns Hopkins | Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| JP2012511024A (ja) | 2008-12-05 | 2012-05-17 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品 |
| US9056841B2 (en) | 2009-03-19 | 2015-06-16 | The Johns Hopkins University | PSMA-targeting compounds and uses thereof |
| AU2012294639B2 (en) | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| ES2729555T3 (es) * | 2011-11-30 | 2019-11-04 | Univ Johns Hopkins | Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos |
| EP3939972A1 (en) * | 2013-01-14 | 2022-01-19 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
| EP3456700A1 (en) * | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN106660943B (zh) * | 2014-05-06 | 2020-03-17 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
| EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active Search and Examination
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172559A patent/JP2026021351A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201813644T1 (tr) | Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. | |
| BR112023015045A2 (pt) | Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| NZ739770A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| EA202090124A1 (ru) | Аденовирус, вооруженный биспецифическим рекрутером t-клеток (bite) | |
| JOP20220020B1 (ar) | مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة | |
| CN106456764A8 (zh) | 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 | |
| Lin et al. | Conditional diagnosability of arrangement graphs under the PMC model | |
| Hoerr et al. | Magnetic resonance imaging characterization of microbial infections | |
| MX386900B (es) | Compuestos para formacion de imagenes de agregados de proteinas tau. | |
| EP3367667A4 (en) | IMAGING DEVICE, ENDOSCOPE AND ENDOSCOPE SYSTEM | |
| EP3410690A4 (en) | IMAGING UNIT, IMAGE MODULE AND ENDOSCOPE | |
| WO2016154542A3 (en) | Compositions and methods for treating cardiovascular related disorders | |
| EA201100674A1 (ru) | Вакцина против вируса африканской чумы лошадей | |
| EP3410691A4 (en) | IMAGING UNIT, IMAGE MODULE AND ENDOSCOPE | |
| CY1124397T1 (el) | Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου | |
| BR112018012660A2 (pt) | composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo | |
| Saidlitz et al. | Amyloid imaging in Alzheimer's disease: a literature review | |
| IT202200006905A1 (it) | Metodo per l'analisi di immagini radiografiche, ed in particolare immagini teleradiografie latero-laterali del cranio, e relativo sistema di analisi. | |
| Garcia | Optimised diagnosis in digital flexor tendon sheath pathology in the horse | |
| Bendyuk et al. | Izuchenie potrebnosti v meditsinskoy pomoshchi u rabotnikov promyshlennogo predpriyatiya | |
| van Gelderen et al. | Exploring a flexible pulse design for studying magnetization transfer | |
| 한진 et al. | An Investigation on the Human Error of Medical Imaging in Mass Media | |
| MX388833B (es) | Compuesto marcado con 18f para diagnostico de cancer de prostata y uso de este | |
| Sangha’s et al. | ANNEXURE-I: RESEARCH INFORMED CONSENT FORM |